<ol>
    <li>Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors
and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. 
        <em>Lancet. </em>2012;380:2224-2260.
    </li>
    <li>Pirie K, Peto R, Reeves GK, et al. The 21st century hazard of smoking and benefits of stopping: a prospective study of one million women in the UK. 
        <em>Lancet. </em>2013;381:133-141.
    </li>
    <li>Morris PB, Ference BA, Jahangir E, et al. Cardiovascular effects of exposure to cigarette smoke and electronic cigarettes: clinical perspectives from the Prevention of Cardiovascular Disease Section Leadership Council and Early Career Councils of the American College of Cardiology. 
        <em>J Am Coll Cardiol</em>. 2015;66:1378-1391.
    </li>
    <li>Hackshaw A, Morris JK, Boniface S, et al. Low cigarette consumption and risk of coronary heart disease and stroke: meta-analysis of 141 cohort studies in 55 study reports. 
        <em>BMJ</em>. 2018;360:j5855.
    </li>
    <li>Hu Y, Zong G, Liu G, et al. Smoking cessation, weight change, type 2 diabetes, and mortality.

        <em>N Engl J Med. </em>2018;379:623-632. 
    </li>
    <li>Godtfredsen NS, Holst C, Prescott E, et al. Smoking reduction, smoking cessation, and mortality: a 16-year follow-up of 19.372 men and women from The Copenhagen Centre for Prospective Population Studies. 
        <em>Am J Epidemiol. </em>2002;156:994-1001. 
    </li>
    <li>Tverdal A, Bjartveit K. Health consequences of reduced dailt cigarette consumption. 
        <em>Tobacco Control. </em>2006;15:472-480.
    </li>
    <li>Gerber Y, Myers V, Goldbourt U. Smoking reduction at midlife and lifetime mortality risk in men: a prospective cohort study. 
        <em>Am J Epidemiol. </em>2012;175:1006-1012. 
    </li>
    <li>Hart C, Gruer L, Bauld L. Does smoking reduction in midlife reduce mortality risk? Results of 2 long-term prospective cohort studies of men and women in Scotland. 
        <em>Am J Epidemiol. </em>2013;178:770-779.
    </li>
    <li>Lindson-Hawley N, Hartmann-Boyce J, Fanshawe TR, et al. Interventions to reduce harm from continued tobacco use. 
        <em>Cochrane Database Syst Rev. </em>2016;10:Cd005231. 
    </li>
    <li>Abrams DB, Glasser AM, Pearson JL, et al. Harm minimization and tobacco control: reframing societal views of nicotine use to rapidly save lives. 
        <em>Annu Rev Public Health. </em>2018;39:193-213. 
    </li>
    <li>Hartmann-Boyce J, Chepkin SC, Ye W, et al. Nicotine replacement therapy versus control for smoking cessation (review). 
        <em>Cochrane Database Sys Rev. </em>2018;5:CD000146.
    </li>
    <li>Cahill K, Stevens S, Perera R, et al. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. 
        <em>Cochrane Database Syst Rev. </em>2013;4:CD006103. 
    </li>
    <li>Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. 
        <em>Cochrane Database Syst Rev. </em>2012;4. 
    </li>
    <li>Cahill K, Lindson-Hawley N, Thomas KH, et al. Nicotine receptor partial agonists for smoking cessation. 
        <em>Cochrane Database Syst Rev. </em>2016;5:CD006103
    </li>
    <li>Gonzales D, Rennard SI, Nides M, et al; for the Varenicline Phase 3 Study Group. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. 
        <em>JAMA</em>. 2006;296:47-55. 
    </li>
    <li>Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. 
        <em>JAMA</em>. 2006;296:56-63. 
    </li>
    <li>Tsai ST, Cho HJ, Cheng HS, et al. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. 
        <em>Clin Ther.</em> 2007;29:1027-1039. 
    </li>
    <li>Wang C, Xiao D, Chan KP, et al. Varenicline for smoking cessation: a placebo-controlled, randomized study. 
        <em>Respirology</em> 2009;14:384-392. 
    </li>
    <li>Bolliger CT, Issa JS, Posadas-Valay R, et al. Effects of varenicline in adult smokers: a multinational, 24-week, randomized, double-blind, placebo-controlled study. 
        <em>Clin Ther. </em>2011;33:465-477. 
    </li>
    <li>Rigotti NA, Pipe AL, Benowitz NL, et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. 
        <em>Circulation. </em>2010; 121:221-229.
    </li>
    <li>Tashkin DP, Rennard S, Hays JT, et al. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. 
        <em>Chest.</em> 2011;139:591-599. 
    </li>
    <li>Anthenelli RM, Morris C, Ramey TS, et al. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial. 
        <em>Ann Int Med</em> 2013;159:390-400. 
    </li>
    <li>Rennard S, Hughes J, Cinciripini PM, et al; Flexible Quit Date Study Group. A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates. 
        <em>Nic Tob Research</em> 2012;14:343-350.
    </li>
    <li>Gonzales D, Hajek P, Pliamm L, et al. Retreatment with varenicline for smoking cessation in smokers who have previously taken varenicline: a randomized, placebo-controlled trial. 
        <em>Clin Pharm Therap.</em> 2014;96:390-396.
    </li>
    <li>Tonstad S, Tønnesen P, Hajek P, et al; Varenicline Phase 3 Study Group. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. 
        <em>JAMA. </em>2006;296:64-71. 
    </li>
    <li>Evins E, Cather C, Pratt SA. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized, clinical trial. 
        <em>JAMA. </em>2014;311:145-154.
    </li>
    <li>Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. 
        <em>Lancet. </em>2016;387:2507-2520.
    </li>
    <li>Barboza JL, Patel R, Patel P, et al. An update on the pharmacotherapeutic interventions for smoking cessation. 
        <em>Expert Opin Pharmacother. </em>2016;17:1483-1496.
    </li>
    <li>Bartsch AL, Härter M, Niedrich J, et al. A systematic literature review
of self-reported smoking cessation counseling by primary care physicians. 
        <em>PLoS One. </em>2016;11:e0168482.
    </li>
    <li>Royal College of Physicians. Nicotine without smoke: Tobacco harm reduction. April 2016. https://www.rcplondon.ac.uk/file/3563/download?token=Mu0K_ZR0. Accessed October 12, 2018.</li>
    <li>McNeill A, Brose LS, Calder R, et al. E-cigarettes: an evidence update. A report commissioned by Public Health England. 2015. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/733022/Ecigarettes_an_evidence_update_A_report_commissioned_by_Public_Health_England_FINAL.pdf. Accessed October 12, 2018.</li>
    <li>McNeill A, Brose LS, Calder R, et al. Evidence review of e-cigarettes and heated tobacco products 2018. A report commissioned by Public Health England. 2018. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/684963/Evidence_review_of_e-cigarettes_and_heated_tobacco_products_2018.pdf. Accessed October 12, 2018.</li>
    <li>Japan Tobacco Inc. Japanese Domestic Cigarette Sales Results for July 2018. August 17, 2018. https://www.jt.com/media/news/2018/pdf/20180817_02.pdf. Accessed October 12, 2018. </li>
    <li>Hajek P, Peerbux S, Philips-Waller A, et al. Interest in using varenicline and its effects in people who both smoke and vape. Poster presented at: Society for Research on Nicotine and Tobacco Europe 18
        <sup>th</sup> Annual Conference; September 6-8, 2018; Munich, Germany. Med-1.
    </li>
    <li>World Health Organization. 
        <em>WHO Framework Convention on Tobacco Control.</em> Geneva, Switzerland; World Health Organization; 2003.
    </li>
    <li>Gulland A, et al. WHO urges restrictions on e-cigarettes. 
        <em>BMJ </em>2016;355:i5991.
    </li>
    <li>National Institute for Health Care Excellence. Stop smoking interventions and services. NICE guideline NG92. March 28, 2018. nice.org.uk/guidance/ng92. Accessed October 12, 2018.</li>
    <li>Verbiest M, Brakema E, van der Kleij R, et al. National guidelines for smoking cessation in
primary care: a literature review and evidence analysis. 
        <em>NPJ Prim Care Respir Med. </em>2017;27:2
    </li>
    <li>Canadian Action Network for the Advancement, Dissemination and Adoption of Practice-informed Tobacco Treatment (CAN-ADAPTT). Canadian Smoking Cessation Clinical Practice Guideline. 2011. https://www.peelregion.ca/health/professionals/events/pdf/2013/canadaptt-summary-statements.pdf. Accessed October 12, 2018. </li>
    <li>Schraufnagel DE, Blasi F, Drummond MB, et al; Forum of International Respiratory Societies. Electronic cigarettes. A position statement of the forum of international respiratory societies. 
        <em>Am J Respir Crit Care Med. </em>2014;190:611-618. 
    </li>
</ol>